A cell-based screening test detected synthetic cannabinoid activity in vape liquids faster and cheaper than traditional chemical analysis — and flagged some CBD-labeled products as containing hidden cannabinoid activity.
Forensic toxicologists, public health agencies monitoring drug supply, emergency physicians treating synthetic cannabinoid intoxication, regulators of vape products.
What the researchers found
Researchers applied a cell-based activity screening method (CB1/β-arrestin2 recruitment assay using the NanoBiT principle) to detect synthetic cannabinoid receptor agonists (SCRAs) in e-liquids — the first time this approach was used on a real patient case.
When applied to an e-liquid from an intoxicated patient, the assay demonstrated strong cannabinoid activity, confirming the presence of SCRAs. Screening a set of 23 commercially available e-liquids identified six that were SCRA-positive.
A surprising finding emerged: five e-liquids showed decreased CB1 activity compared to controls, suggesting they contained cannabinoid antagonists or substances that interfered with normal receptor function. This unexpected finding highlights that the safety concerns extend beyond simple SCRA contamination.
The approach offers advantages over traditional methods like mass spectrometry: it's faster, cheaper, doesn't require constantly updated chemical libraries, and detects any substance with cannabinoid activity regardless of whether its specific structure has been previously identified. This last point is critical because new synthetic cannabinoids appear faster than reference libraries can be updated.
Why it matters
Synthetic cannabinoids in vape products are a growing public health problem, and detection methods can't keep up with the pace of new compound introduction. Activity-based screening detects what a substance does (activates cannabinoid receptors) rather than what it looks like chemically — meaning it can catch novel compounds that traditional analytical methods would miss. This could transform how quickly public health authorities identify dangerous products.
The numbers in context
23 e-liquids screened. 6 SCRA-positive. 5 showed decreased CB1 activity (unexpected finding). 1 patient case e-liquid confirmed SCRA-positive. Activity-based method faster and cheaper than mass spectrometry.
How the study worked
Applied an in vitro CB1/β-arrestin2 recruitment assay (NanoBiT principle) to screen e-liquids for cannabinoid activity. Tested one e-liquid from an intoxicated patient and 23 commercially available e-liquids. Compared activity-based results with traditional analytical detection methods.
Who was studied
23 e-liquids tested for synthetic cannabinoid receptor agonists.
What this study cannot tell us
The assay detects CB1 receptor activity but cannot identify the specific compound responsible. It may not detect compounds that act through non-CB1 mechanisms. The 23-product sample is small and may not represent the full e-liquid market. The method requires laboratory equipment and cannot be used as a point-of-care test. False positives from naturally occurring cannabinoids in hemp-derived products need to be considered.
How to read the evidence
Laboratory methodology study demonstrating a novel screening approach — provides proof of concept but not yet validated for large-scale surveillance programs.
When this study was published
Published in 2026, introducing a detection approach designed to keep pace with the rapidly evolving synthetic cannabinoid market.
The bigger picture
This detection technology addresses a gap identified in the semi-synthetic cannabinoid review (RTHC-00234) and connects to the synthetic cannabinoid potency testing (RTHC-00277). Those studies showed that new compounds emerge faster than they can be structurally identified; this assay sidesteps that problem by measuring biological activity directly. The finding that some CBD-labeled products contained hidden cannabinoid activity echoes the product quality concerns raised across multiple studies.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Could this activity-based screening be adapted for point-of-care or field use by law enforcement? What are the five e-liquids with decreased CB1 activity actually containing? Should activity-based screening become standard for e-liquid market surveillance?
Read the original research
Fast and reliable in vitro activity-based detection of synthetic cannabinoid receptor agonists in e-liquids.
Archives of toxicology, 100(1), 291-304
Archives of Toxicology is a peer-reviewed journal focusing on the toxicological effects of substances.
Citation
Timmerman, Axelle; Lyphout, Cathelijne; Verougstraete, Nick; Coopman, Vera; Stove, Christophe. (2026). Fast and reliable in vitro activity-based detection of synthetic cannabinoid receptor agonists in e-liquids.. Archives of toxicology, 100(1), 291-304. https://doi.org/10.1007/s00204-025-04193-y
Explore the wider topic
- Surviving 4/20 Sober: A Practical Survival Guide
- CBT for Cannabis Recovery: How Cognitive Behavioral Therapy Works
- THC Purity and Potency: What the Label Actually Means
- The Cannabis Relapse Cycle: Quit, Feel Good, Get Complacent, Repeat
- Cold Turkey vs Tapering: Which Way to Quit Weed
- Dab and Concentrate Withdrawal: Why It Hits Harder
- Dating Sober After Years of Being High: What Nobody Tells You
- Delta-8 THC: Addiction, Withdrawal, and What We Don't Know
- Edible Addiction and Withdrawal: What Makes It Different
- Edibles and Psychosis: When a Bad Trip Becomes an Emergency
- Exercise as Medicine: Working Out After Quitting Weed
- Grieving Weed Itself: Mourning the Loss of a Companion
- Vaping vs Smoking vs Edibles: A Harm Reduction Guide
- How to Help Someone Quit Weed (When They're Not Ready)
- How Cannabis Products Are Made: From Plant to Concentrate to Edible
- How to Quit Weed: A No-Judgment Step by Step Guide
- Journaling Through Weed Withdrawal: Why Writing Helps You Heal
- Laced Weed and Contaminated Vapes: Real Risks vs Myths
- Legal vs Street Weed: Quality, Safety, and What You're Actually Smoking
- MA vs SMART Recovery vs Therapy: Comparing Your Options
- Meditation and Mindfulness for Weed Withdrawal
- Your Partner Still Smokes Weed: How to Navigate It
- Quitting Weed While Your Partner Still Smokes
- The Pink Cloud Effect: When Quitting Weed Feels Too Good
- How to Quit Smoking Weed Cold Turkey: What to Expect
- Quit Weed or Cut Back: Which Is Right for You?
- I Quit Weed and Regret It: An Honest Look at Non-Linear Recovery
- Quitting Weed Pens and Dabs: Why Concentrates Hit Different
- Quitting Edibles: Is Withdrawal Different from Smoking?
- Quitting Weed in Your 20s: Career, Social Life, Starting Over
- Quitting Weed in Your 30s: It's Not Too Late
- Quitting Weed After 10+ Years of Daily Use: What to Expect
- Quitting Weed During a Life Crisis: Divorce, Job Loss, and Other Bad Timing
- Quitting Weed and Working Out: How Exercise Helps Recovery
- Quitting Weed After Loss: When Grief Comes Flooding Back
- Quitting Weed When It's Legal Everywhere
- Weed Withdrawal Success Stories: Real People Who Made It Through
- Quitting Weed Long Distance: When You Can't Remove Triggers
- I Relapsed on Weed. Now What? A Practical Reset Guide
- I Relapsed After Quitting Weed: What Now?
- Sativa vs Indica: The Myth and the Science Behind Cannabis Strain Labels
- Should I Quit Weed? A Decision Framework (Not a Lecture)
- Quitting Weed at Music Festivals and Concerts: A Sober Survival Guide
- Supplements That Actually Help with Weed Withdrawal (And Ones That Don't)
- How to Tell Your Friends You're Quitting Weed
- Why Is Weed Withdrawal Worse Now Than 20 Years Ago?
- Relapse Prevention Plan for Cannabis: A CBT-Based Approach
- Why Weed Relapse Happens: The Science Behind Going Back
- Replacing the Ritual: What to Do When You Quit Weed
- How Cannabis Damaged My Relationships: Before and After
- Social Media Detox from Weed Content